Next Article in Journal
A Multi-Center Cohort Study on Characteristics of Pain, Its Impact and Pharmacotherapeutic Management in Patients with ALS
Previous Article in Journal
Implications for Early Diagnosis and Treatment in Schizophrenia Due to Correlation between Auditory Perceptual Deficits and Cognitive Impairment
Article

Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone

1
Addiction Unit, Sørlandet Hospital HF, 4604 Kristiansand, Norway
2
Norwegian Centre for Addiction Research, University of Oslo, 0315 Oslo, Norway
3
Mental Health Services, Akershus University Hospital, Lørenskog, 1478 Oslo, Norway
4
Center for Mental Health and Substance Abuse, University of South-Eastern Norway, 3040 Drammen, Norway
5
Vestfold Hospital Trust, 3103 Toensberg, Norway
6
Department of R&D in Psychiatric Health Care, Akershus University Hospital, 1478 Oslo, Norway
7
Faculty for Health Science, Oslo Metropolitan University, 0130 Oslo, Norway
*
Author to whom correspondence should be addressed.
Academic Editors: Morten Hesse and Birgitte Thylstrup
J. Clin. Med. 2021, 10(19), 4558; https://doi.org/10.3390/jcm10194558
Received: 3 September 2021 / Revised: 24 September 2021 / Accepted: 29 September 2021 / Published: 30 September 2021
The level of impulsivity, hyperactivity, and inattention (IHI) is higher among patients with substance use disorder (SUD) than in the general population. However, the prevalence of such symptoms in patients seeking treatment with an opioid antagonist, such as extended-release naltrexone (XR-NTX), is unknown. We screened 162 patients with opioid use disorder (OUD) seeking treatment with XR-NTX in Norway using the Adult ADHD Self-Report Scale (ASRS) to estimate the prevalence of IHI alongside an assessment of mental and physical health and substance use. Sixty-six patients scored above the clinical cut-off on the ASRS. Higher levels of IHI were significantly associated with a longer history of frequent amphetamine use, current alcohol use, and greater mental distress. Mental distress was the strongest factor associated with higher levels of IHI. The introduction of screening for IHI and mental distress in opioid maintenance treatment and XR-NTX would likely improve the quality of care and enable clinicians to tailor interventions to the needs of patients with high levels of IHI to prevent treatment discontinuation. View Full-Text
Keywords: extended-release naltrexone; opioid dependence; mental distress; impulsivity extended-release naltrexone; opioid dependence; mental distress; impulsivity
MDPI and ACS Style

Karlsson, A.T.; Vederhus, J.-K.; Clausen, T.; Weimand, B.; Solli, K.K.; Tanum, L. Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone. J. Clin. Med. 2021, 10, 4558. https://doi.org/10.3390/jcm10194558

AMA Style

Karlsson AT, Vederhus J-K, Clausen T, Weimand B, Solli KK, Tanum L. Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone. Journal of Clinical Medicine. 2021; 10(19):4558. https://doi.org/10.3390/jcm10194558

Chicago/Turabian Style

Karlsson, Ann T., John-Kåre Vederhus, Thomas Clausen, Bente Weimand, Kristin K. Solli, and Lars Tanum. 2021. "Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone" Journal of Clinical Medicine 10, no. 19: 4558. https://doi.org/10.3390/jcm10194558

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop